LINC00528 Regulates Myocardial Infarction by Targeting the miR-143-3p/COX-2 Axis

Bioengineered - United Kingdom
doi 10.1080/21655979.2019.1704535
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

MicroRNA-143 (miR-143) Regulates Cancer Glycolysis via Targeting Hexokinase 2 Gene

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2012English

miR-483-3p Regulates Acute Myocardial Infarction by Transcriptionally Repressing Insulin Growth Factor 1 Expression

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

miR‑144‑3p Regulates the Resistance of Lung Cancer to Cisplatin by Targeting Nrf2

Oncology Reports
MedicineCancer ResearchOncology
2018English

miR-17-3P Regulates the Proliferation and Survival of Colon Cancer Cells by Targeting Par4

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2017English

LncRNA NR_038323 Suppresses Renal Fibrosis in Diabetic Nephropathy by Targeting miR-324-3p/DUSP1 Axis

Molecular Therapy - Nucleic Acids
Drug DiscoveryMolecular Medicine
2019English

miR-185-3p Regulates the Invasion and Metastasis of Nasopharyngeal Carcinoma by Targeting WNT2B In�vitro

Oncology Letters
Cancer ResearchOncology
2017English

miR-143 Promotes Angiogenesis and Osteoblast Differentiation by Targeting HDAC7

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2020English

lncRNA CASC2/miR‑18a‑5p Axis Regulates the Malignant Potential of Nasopharyngeal Carcinoma by Targeting RBBP8

Oncology Reports
MedicineCancer ResearchOncology
2018English

miR-302a-5p/367-3p-HMGA2 Axis Regulates Malignant Processes During Endometrial Cancer Development

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy